Cargando…

Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma

PURPOSE: The objective of this study is to estimate radiotherapy (RT) modalities for patients with stage I-II nasal natural killer T-Cell lymphoma (NNKTCL), including plan quality, radiation delivery efficiency, cost of RT and excess absolute risk (EAR). MATERIALS AND METHODS: Twenty-four representa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xianfeng, Wu, Furong, Guo, Qishuai, Wang, Ying, He, Yanan, Luo, Huanli, Li, Qicheng, Zhong, Mingsong, Li, Chao, Yang, Han, Zhou, Juan, Jin, Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681560/
https://www.ncbi.nlm.nih.gov/pubmed/31534370
http://dx.doi.org/10.2147/CMAR.S201514
_version_ 1783441747428245504
author Liu, Xianfeng
Wu, Furong
Guo, Qishuai
Wang, Ying
He, Yanan
Luo, Huanli
Li, Qicheng
Zhong, Mingsong
Li, Chao
Yang, Han
Zhou, Juan
Jin, Fu
author_facet Liu, Xianfeng
Wu, Furong
Guo, Qishuai
Wang, Ying
He, Yanan
Luo, Huanli
Li, Qicheng
Zhong, Mingsong
Li, Chao
Yang, Han
Zhou, Juan
Jin, Fu
author_sort Liu, Xianfeng
collection PubMed
description PURPOSE: The objective of this study is to estimate radiotherapy (RT) modalities for patients with stage I-II nasal natural killer T-Cell lymphoma (NNKTCL), including plan quality, radiation delivery efficiency, cost of RT and excess absolute risk (EAR). MATERIALS AND METHODS: Twenty-four representative patients with stage I-II NNKTCL treated with fix-field intensity-modulated radiotherapy (FF-IMRT) were re-planned for volumetric modulated arc therapy (VMAT), TomoDirect (TD) and TomoHelical (TH) on the TomoHDA system, respectively. Plan characteristics, cost of RT and EAR were compared. RESULTS: Compared with IMRT, TD and TH showed significant improvement in terms of D(98%), D(2%), cold spot volume and homogeneity index (HI) of planning target volume (PTV), while achieving worse D(mean) and conformity index (CI). The mean dose of oropharynx, thyroid and left salivary, and the maximum dose of right salivary by TD (249.20%, p=0.000; 52.94%, p=0.000; 160.23%, p=0.022; 122.67%, p=0.027), VMAT (15.76%, p=0.000; 23.53%, p=0.000; 34.09%, p=0.000; 31.33%, p=0.000) and TH (250.32%, p=0.000; 58.82%, p=0.000; 120.45%, p=0.020; 117.33%, p=0.032) increased significantly compared to IMRT. VMAT reduced treatment time (p=0.000; 0.000; 0.000) and monitor units (MUs) (p=0.000; 0.000; 0.000) obviously compared with IMRT, TD and TH. The cost of RT for TD and TH increased 150% compared with IMRT and VMAT. IMRT obtained the lowest EAR to oropharynx, thyroid, left and right salivary gland in the four treatment modalities. CONCLUSION: The results show that both TD and TH can achieve higher conformal target quality while getting worse organs at risk (OARs) sparing and EAR to some organs than IMRT for patients with stage I-II NNKTCL. IMRT delivers the lowest dose to most OARs, VMAT requires the lower cost of RT and shortest delivery time, and TH obtained the optimal target coverage. The results could provide direction for selecting proper RT modalities for different cases.
format Online
Article
Text
id pubmed-6681560
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66815602019-09-18 Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma Liu, Xianfeng Wu, Furong Guo, Qishuai Wang, Ying He, Yanan Luo, Huanli Li, Qicheng Zhong, Mingsong Li, Chao Yang, Han Zhou, Juan Jin, Fu Cancer Manag Res Original Research PURPOSE: The objective of this study is to estimate radiotherapy (RT) modalities for patients with stage I-II nasal natural killer T-Cell lymphoma (NNKTCL), including plan quality, radiation delivery efficiency, cost of RT and excess absolute risk (EAR). MATERIALS AND METHODS: Twenty-four representative patients with stage I-II NNKTCL treated with fix-field intensity-modulated radiotherapy (FF-IMRT) were re-planned for volumetric modulated arc therapy (VMAT), TomoDirect (TD) and TomoHelical (TH) on the TomoHDA system, respectively. Plan characteristics, cost of RT and EAR were compared. RESULTS: Compared with IMRT, TD and TH showed significant improvement in terms of D(98%), D(2%), cold spot volume and homogeneity index (HI) of planning target volume (PTV), while achieving worse D(mean) and conformity index (CI). The mean dose of oropharynx, thyroid and left salivary, and the maximum dose of right salivary by TD (249.20%, p=0.000; 52.94%, p=0.000; 160.23%, p=0.022; 122.67%, p=0.027), VMAT (15.76%, p=0.000; 23.53%, p=0.000; 34.09%, p=0.000; 31.33%, p=0.000) and TH (250.32%, p=0.000; 58.82%, p=0.000; 120.45%, p=0.020; 117.33%, p=0.032) increased significantly compared to IMRT. VMAT reduced treatment time (p=0.000; 0.000; 0.000) and monitor units (MUs) (p=0.000; 0.000; 0.000) obviously compared with IMRT, TD and TH. The cost of RT for TD and TH increased 150% compared with IMRT and VMAT. IMRT obtained the lowest EAR to oropharynx, thyroid, left and right salivary gland in the four treatment modalities. CONCLUSION: The results show that both TD and TH can achieve higher conformal target quality while getting worse organs at risk (OARs) sparing and EAR to some organs than IMRT for patients with stage I-II NNKTCL. IMRT delivers the lowest dose to most OARs, VMAT requires the lower cost of RT and shortest delivery time, and TH obtained the optimal target coverage. The results could provide direction for selecting proper RT modalities for different cases. Dove 2019-07-30 /pmc/articles/PMC6681560/ /pubmed/31534370 http://dx.doi.org/10.2147/CMAR.S201514 Text en © 2019 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liu, Xianfeng
Wu, Furong
Guo, Qishuai
Wang, Ying
He, Yanan
Luo, Huanli
Li, Qicheng
Zhong, Mingsong
Li, Chao
Yang, Han
Zhou, Juan
Jin, Fu
Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma
title Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma
title_full Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma
title_fullStr Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma
title_full_unstemmed Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma
title_short Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma
title_sort estimation of radiotherapy modalities for patients with stage i-ii nasal natural killer t-cell lymphoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681560/
https://www.ncbi.nlm.nih.gov/pubmed/31534370
http://dx.doi.org/10.2147/CMAR.S201514
work_keys_str_mv AT liuxianfeng estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT wufurong estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT guoqishuai estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT wangying estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT heyanan estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT luohuanli estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT liqicheng estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT zhongmingsong estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT lichao estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT yanghan estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT zhoujuan estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma
AT jinfu estimationofradiotherapymodalitiesforpatientswithstageiiinasalnaturalkillertcelllymphoma